1MeCullough PA. Clinical applications of B-type natriuretie peptide levels in the care of cardiovascular patients. Minerva Cardioangiol,2004, 52:479-489.
2Sudoh T, Kangawa K, Minamino N,et al. A natriuretic peptide in porcine brain. Nature, 1988, 322:78-81.
4Yoshimura M, Yasue H, Morita E, et ai. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation, 1991, 84:1581-1588.
5Connel JMC, Davies E. The new biology of aldosterone. J Endocrinol, 2005, 186:1-20.
6Yoshizumi M, Tsuji H, Nishmura H, et al. Natriuretic peptides regulate the expression of tissue factor and PAI-1 in endothelial cells.Thromb Haemost, 1999, 82 : 1497-1503.
7Zellner, C, Protter AA, Ko E, et al. Coronary vasodilator effects of BNP: mechanisms of action in coronary conductance and resistance arteries. Am J Physiol Heart Circ Physiol, 1999, 276: H1049-H1057.
8Hobbs RE, Miller LW, Bott-Silverman C, et al. Hemodynamic effects of a single intravenous injection of synthetic human brain natriuretic peptide in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol, 1996, 78:896-901.
9Marcus LS, Hart D, Packer M, et al. Hemodynamic and renal excretory effects of human brain natriuretic paptide in fusion inpatients with congestive heart failure. A double-blind, placebocontrolled, randomized crossover trial. Circulation, 1996, 94:3184-3189.
10Abraham WT, Lowes BD, Ferguson DA, et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail, 1998,4:37-44.
